FDA Inspection
Pfizer Inc.Pfizer Inc. – FDA Inspection, Sep 29, 2026
Record Details
This FDA Inspection record concerns Pfizer Inc., with an inspection on September 29, 2026, issued by the New Jersey District Office, covering human drugs.
View Company Profile
ID · 4057bc9d-ffe0-4d70-ab21-41af1cfacb04
Inspection Facts
- Inspection number
- 1338628
- FDA center
- Human Drugs
- Project area
- Postmarket Surv. and Epidemiology
- Outcome
- Form 483 issued
FDA Citations
1- FDCA 505-1(f)(4)Failure to comply with REMS Implementation System
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Pfizer Inc.
5| Date | Classification | Office | Project area |
|---|---|---|---|
| June 18, 2025 | Not classified | New Jersey District Office | |
| September 28, 2022 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 2, 2016 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 5, 2013 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| March 11, 2011 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Pfizer Inc.
- FDA Inspection 1256978 - 2025-06-18
- FDA Inspection 1181324 - 2022-09-28
- FDA Inspection 971684 - 2016-06-02
- FDA Inspection 847159 - 2013-09-05
- FDA Inspection 714537 - 2011-03-11
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.